X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Novartis with Fresenius Kabi Onco. - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs FRESENIUS KABI ONCO. - Comparison Results

NOVARTIS    Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

FRESENIUS KABI ONCO. 
   Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NOVARTIS FRESENIUS KABI ONCO. NOVARTIS/
FRESENIUS KABI ONCO.
 
P/E (TTM) x 347.8 22.1 1,571.6% View Chart
P/BV x 17.1 3.1 550.1% View Chart
Dividend Yield % 1.7 0.0 -  

Financials

 NOVARTIS   FRESENIUS KABI ONCO.
EQUITY SHARE DATA
    NOVARTIS
Mar-16
FRESENIUS KABI ONCO.
Mar-13
NOVARTIS/
FRESENIUS KABI ONCO.
5-Yr Chart
Click to enlarge
High Rs982176 558.0%   
Low Rs55679 708.5%   
Sales per share (Unadj.) Rs252.937.7 671.1%  
Earnings per share (Unadj.) Rs62.15.1 1,220.1%  
Cash flow per share (Unadj.) Rs63.36.7 941.4%  
Dividends per share (Unadj.) Rs10.000-  
Dividend yield (eoy) %1.30-  
Book value per share (Unadj.) Rs363.642.5 854.7%  
Shares outstanding (eoy) m31.96158.23 20.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.03.4 90.1%   
Avg P/E ratio x12.425.0 49.5%  
P/CF ratio (eoy) x12.218.9 64.2%  
Price / Book Value ratio x2.13.0 70.7%  
Dividend payout %16.10-   
Avg Mkt Cap Rs m24,58020,135 122.1%   
No. of employees `0000.81.2 65.3%   
Total wages/salary Rs m1,801703 256.1%   
Avg. sales/employee Rs Th10,748.95,176.2 207.7%   
Avg. wages/employee Rs Th2,395.2610.4 392.4%   
Avg. net profit/employee Rs Th2,641.1699.6 377.5%   
INCOME DATA
Net Sales Rs m8,0835,963 135.6%  
Other income Rs m82918 4,607.8%   
Total revenues Rs m8,9135,981 149.0%   
Gross profit Rs m2341,430 16.4%  
Depreciation Rs m37258 14.2%   
Interest Rs m2-26 -6.9%   
Profit before tax Rs m1,0251,216 84.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m170-   
Extraordinary Inc (Exp) Rs m1,696-68 -2,490.9%   
Tax Rs m752342 219.8%   
Profit after tax Rs m1,986806 246.4%  
Gross profit margin %2.924.0 12.1%  
Effective tax rate %73.428.1 260.7%   
Net profit margin %24.613.5 181.8%  
BALANCE SHEET DATA
Current assets Rs m12,6785,102 248.5%   
Current liabilities Rs m2,4332,385 102.0%   
Net working cap to sales %126.745.6 278.2%  
Current ratio x5.22.1 243.6%  
Inventory Days Days33150 21.8%  
Debtors Days Days22113 19.8%  
Net fixed assets Rs m695,148 1.3%   
Share capital Rs m160158 101.0%   
"Free" reserves Rs m11,4606,556 174.8%   
Net worth Rs m11,6216,732 172.6%   
Long term debt Rs m0952 0.0%   
Total assets Rs m14,40010,388 138.6%  
Interest coverage x570.5-45.8 -1,246.3%   
Debt to equity ratio x00.1 0.0%  
Sales to assets ratio x0.60.6 97.8%   
Return on assets %13.87.5 183.9%  
Return on equity %17.112.0 142.8%  
Return on capital %23.614.6 161.4%  
Exports to sales %0.774.5 1.0%   
Imports to sales %18.624.8 75.0%   
Exports (fob) Rs m604,441 1.4%   
Imports (cif) Rs m1,5031,477 101.7%   
Fx inflow Rs m1865,298 3.5%   
Fx outflow Rs m1,8211,772 102.7%   
Net fx Rs m-1,6353,525 -46.4%   
CASH FLOW
From Operations Rs m2,5311,274 198.6%  
From Investments Rs m-8,270-1,204 686.7%  
From Financial Activity Rs m-386-196 196.7%  
Net Cashflow Rs m-6,125-126 4,849.2%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 75.0 81.0 92.6%  
Indian inst/Mut Fund % 2.0 0.3 666.7%  
FIIs % 1.6 9.6 16.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.5 9.1 236.3%  
Shareholders   41,647 42,599 97.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NOVARTIS With:   CADILA HEALTHCARE  TTK HEALTHCARE  SHASUN PHARMA  BIOCON LTD  J.B.CHEMICALS  

Compare NOVARTIS With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Global Markets Remain Volatile Ahead of US Growth Concerns(RoundUp)

Benchmark indices in US corrected marginally by 0.8% during the week. Minutes of Federal Reserve's July meeting are out and the situation looks to be in favor of the emerging markets.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Aug 18, 2017 (Close)

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NOVARTIS - FULFORD INDIA COMPARISON

COMPARE NOVARTIS WITH

MARKET STATS